Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2024: USD -5.92

Benitec Biopharma Inc. EPS (Diluted) is USD -5.92 for the Trailing 12 Months (TTM) ending September 30, 2024, a 48.57% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Benitec Biopharma Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -11.51, a 67.83% change year over year.
Benitec Biopharma Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -35.78, a 23.87% change year over year.
Benitec Biopharma Inc. EPS (Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -47.00.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years